Di(pentan-3-yl) ((1S)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methyl)phosphoramidate

Catalog No. :
ACXBJJ132
CAS No. :
1633006-75-3
Molecular Formula :
C29H44N3O3P
Molecular Weight :
513.66

IUPAC Name:di(pentan-3-yl) ((1S)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methyl)phosphoramidate

Di(pentan-3-yl) ((1S)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methyl)phosphoramidate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameDi(pentan-3-yl) ((1S)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methyl)phosphoramidate
IUPAC Namedi(pentan-3-yl) ((1S)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methyl)phosphoramidate
Molecular FormulaC29H44N3O3P
Molecular Weight513.66
SMILESO=P(OC(CC)CC)(N[C@H](C1N2CCC(C1)C(C=C)C2)C3=CC=NC4=CC=CC=C34)OC(CC)CC
InChI KeyNRRLUMCGTMSXAE-XFTQWKANSA-N
SynonymN-(9S)-cinchonan-9-yl-Phosphoramidic acid dipentan-3-yl ester;3-pentyl-CDPA;Phosphoramidic acid, N-(8α,9S)-cinchonan-9-yl-, bis(1-ethylpropyl) ester
CAS No.1633006-75-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACXBJJ132 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXBJJ132 route product structure diagram
    ACXBJJ1321633006-75-3
Inquiry

2. ACXBJJ132 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXBJJ132 route product structure diagram
    ACXBJJ1321633006-75-3
Inquiry

Comments (0)